Serum Uric Acid and Coronary Heart Disease in 9,458 Incident Cases and 155,084 Controls: Prospective Study and Meta-Analysis

Jeremy G. Wheeler¹, Kelsey D. M. Juzwishin¹, Gudny Eiriksdottir², Vilmundur Gudnason², John Danesh¹*

¹ Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, United Kingdom, ² Icelandic Heart Association, Kopavogur, Iceland

Competing Interests: The authors have declared that no competing interests exist. JD is a member of the editorial board of PLOS Medicine.

Author Contributions: JGW, KDMJ, GE, VG, and JD designed the study. JGW, KDMJ, GE, VG, and JD analyzed the data. JGW conducted statistical analyses. JGW, KDMJ, GE, VG, and JD contributed to writing the paper.

Academic Editor: Anthony Keech, University of Sydney, Australia

Citation: Wheeler JG, Juzwishin KDM, Eiriksdottir G, Gudnason V, Danesh J (2005) Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. PLoS Med 2(3): e76.

Received: December 4, 2004
Accepted: January 24, 2005
Published: March 29, 2005

DOI: 10.1371/journal.pmed.0020076

Copyright: © 2005 Wheeler. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abbreviations: CHD, coronary heart disease; CI, confidence interval; MI, myocardial infarction; SD, standard deviation

*To whom correspondence should be addressed. E-mail: john.danesh@phpc.cam.ac.uk

ABSTRACT

Background

It has been suggested throughout the past fifty years that serum uric acid concentrations can help predict the future risk of coronary heart disease (CHD), but the epidemiological evidence is uncertain.

Methods and Findings

We report a “nested” case-control comparison within a prospective study in Reykjavik, Iceland, using baseline values of serum uric acid in 2,456 incident CHD cases and in 3,962 age- and sex-matched controls, plus paired serum uric acid measurements taken at baseline and, on average, 12 y later in 379 participants. In addition, we conducted a meta-analysis of 15 other prospective studies in eight countries conducted in essentially general populations. Compared with individuals in the bottom third of baseline measurements of serum uric acid in the Reykjavik study, those in the top third had an age- and sex-adjusted odds ratio for CHD of 1.39 (95% confidence interval [CI], 1.23–1.58) which fell to 1.12 (CI, 0.97–1.30) after adjustment for smoking and other established risk factors. Overall, in a combined analysis of 9,458 cases and 155,084 controls in all 16 relevant prospective studies, the odds ratio was 1.13 (CI, 1.07–1.20), but it was only 1.02 (CI, 0.91–1.14) in the eight studies with more complete adjustment for possible confounders.

Conclusions

Measurement of serum uric acid levels is unlikely to enhance usefully the prediction of CHD, and this factor is unlikely to be a major determinant of the disease in general populations.
Methods

The Reykjavik Study

The Reykjavik Study, initiated in 1967 as a prospective study of cardiovascular disease, has been described in detail previously [7]. All men born between 1907 and 1934 and all women born between 1908 and 1935 who were resident in Reykjavik, Iceland, and its adjacent communities on 01 December 1966 were identified in the national population register and then invited to participate in the Reykjavik Study during five stages of recruitment between 1967 and 1991, yielding 8,888 male and 9,681 female participants without a history of MI (72% response rate). Nurses administered questionnaires, made physical measurements, recorded an electrocardiogram, performed spirometry, and collected fasting venous blood samples, which were stored at −20 °C for subsequent analysis. All participants have been monitored subsequently for all-cause mortality and for cardiovascular morbidity, with a loss to follow-up of less than 1% to date. A total of 2,459 men and women with available serum samples had major coronary events between the beginning of follow-up and 31 December 1995, yielding mean durations of follow-up among CHD cases of 17.5 (standard deviation [SD] 8.7) years and, among controls, of 20.6 (SD, 8.2) years. In total, 1,073 CHD deaths and 701 nonfatal MIs were recorded among men (including 564 confirmed MIs and 137 possible MIs), and 385 CHD deaths and 300 nonfatal MIs among women (including 237 confirmed MIs and 63 possible MIs). Deaths from coronary heart disease were ascertained from central registers on the basis of a death certificate with International Classification of Diseases codes 410–414, and the diagnosis of nonfatal MI was based on MONICA criteria. We selected 3,969 controls that were “frequency-matched” to cases on calendar year of recruitment, sex, and age in 5-y bands from among participants who had survived to the end of the study period without a MI. The National Bioethics Committee and the Data Protection Authority of Iceland approved the study protocol, and participants provided informed consent.

Laboratory Methods

Serum uric acid levels were measured with a Technicon autoanalyzer [8]. The measurement of other biochemical analytes has been described previously [7]. Baseline measurements of serum uric acid were available on 2,456 out of 2,459 CHD cases and 3,962 out of 3,969 controls. To assess the within-person consistency of serum uric acid levels over time, measurements were made in pairs of samples collected at an interval of about 12 y apart in 379 individuals in the present study.

Statistical Methods and Meta-Analysis

Case-control comparisons were made by unmatched stratified logistic regression fitted by unconditional maximum likelihood. Analysis of serum uric acid values was previously specified to be by sex-specific thirds of values in the controls (with subsidiary analyses involving other cut-off values). Adjustment was made for age, sex, smoking status

Table 1. Characteristics of Uric Acid

| Feature                  | Characteristic                        |
|--------------------------|---------------------------------------|
| Description              | End point of purine metabolism in humans. The majority of uric acid is reabsorbed by the kidney, while the remainder is excreted in urine. Over- or underproduction of uric acid may cause gouty arthritis. |
| Vascular effects         | None directly established but suggested mechanisms include: formation of free radicals; enhanced platelet adhesiveness and aggregation; oxidation of LDL; renal involvement in hypertension |
| Main site of synthesis   | Liver                                 |
| Main correlates          | Male sex; blood pressure, lipids (in particular triglycerides); antihypertensive treatment; history of CHD; obesity; high-purine diet; alcohol intake; insulin resistance; black ethnicity; menopause |
| Baseline serum concentration\* | Men: 320 (70) μmol/l; (5.4 [1.1] mg/dl); women: 270 (70) μmol/l; (4.5 [1.1] mg/dl) |
| Self-correlation\*       | 0.6                                   |

* Values are mean (SD); \* Conversion to SI units: 1 μmol/l = 59.48 mg/dl
\* Approximate correlation between two measurements taken some years apart in the same individuals.
Table 2. Baseline Characteristics of Cases and Controls in the Reykjavik Study

| Category                  | Characteristic                      | Cases (n = 2,459) | Controls (n = 3,969) | p Value |
|---------------------------|-------------------------------------|-------------------|----------------------|---------|
| Demographic               | Age (y)                             | 55.8 (9.3)        | 55.7 (9.1)           | Matched |
|                           | Male, n (%)                         | 1,774 (72)        | 2,743 (69)           | Matched |
| Questionnaire             | Current smokers (including cigarettes, cigars, pipe), n (%) | 1,417 (58)        | 1,941 (49)           | < 0.001 |
|                           | Current cigarette smokers, n (%)    | 962 (39)          | 1,266 (32)           | < 0.001 |
|                           | History of diabetes, n (%)          | 83 (3)            | 63 (2)               | < 0.001 |
|                           | Nonmanual occupation*, n (%)        | 703 (40)          | 1,227 (42)           | 0.15    |
|                           | Education beyond high school**, n (%)| 354 (27)          | 645 (30)             | 0.12    |
|                           | Home owner†, n (%)                  | 1,962 (84)        | 2,201 (85)           | 0.39    |
| Physical measurements     | House Lives in apartment block‡, n (%) | 1,186 (53)       | 1,833 (50)           |         |
|                           | Height (m)                          | 1.71 (0.09)       | 1.72 (0.09)          | 0.07    |
|                           | Weight (kg)                         | 76 (14)           | 75 (14)              | < 0.001 |
|                           | Body mass index (kg/m²)             | 26 (3.9)          | 25 (3.7)             | < 0.001 |
|                           | Systolic blood pressure (mm Hg)     | 146 (22)          | 141 (20)             | < 0.001 |
|                           | Diastolic blood pressure (mm Hg)    | 89 (11)           | 87 (11)              | < 0.001 |
|                           | Forced expiratory volume (l/s)      | 2.8 (0.85)        | 2.9 (0.86)           | 0.002   |
|                           | Protein or sugar present in urine, n (%) | 112 (5)         | 102 (3)              | < 0.001 |
| Blood sample              | Serum uric acid (μmol/l)            | 312 (73)          | 300 (66)             | < 0.001 |
|                           | Total serum cholesterol (mmol/l)    | 6.82 (1.18)       | 6.40 (1.14)          | < 0.001 |
|                           | Serum triglycerides (mmol/l)        | 1.19 (0.79)       | 1.03 (0.62)          | < 0.001 |
|                           | Fasting glucose (mmol/l)            | 4.6 (1.1)         | 4.5 (0.8)            | < 0.001 |
|                           | Serum creatinine (μmol/l)           | 77 (14)           | 75 (13)              | < 0.001 |
|                           | Hemoglobin (mmol/l)                 | 9.2 (0.80)        | 9.1 (0.81)           | < 0.001 |
|                           | Hematocrit (%)                      | 45 (3.6)          | 44 (3.5)             | < 0.001 |
| Inflammatory markers      | C-reactive protein (mg/l)           | 1.75 (5.3)        | 1.28 (5.2)           | < 0.001 |
|                           | von Willebrand factor (IU/dl)       | 107.4 (48)        | 103.2 (46)           | < 0.001 |
|                           | Erythrocyte sedimentation rate (mm/first h) | 7.4 (10.6)  | 6.3 (9.7)            | < 0.001 |

Values are mean (SD) unless indicated otherwise.

* Information on occupation was available for only 1,742 cases and 2,888 controls, respectively.
** Information on education was available for only 1,292 cases and 2,157 controls, respectively.
† Information on home ownership was available for 2,323 cases and 3,754 controls, respectively.
‡ Information on type of residence was available for 2,258 cases and 3,646 controls, respectively. Other categories included “duplex” and “villa.”
§ Information on serum uric acid was available for 2,456 cases and 3,962 controls, respectively.
¶ Value log transformed for analysis and presented as geometric mean (SD).

For the meta-analysis, studies of serum uric acid and CHD published before May 2003 with greater than a year's follow-up conducted in essentially general populations (i.e., excluding cohorts defined on the basis of preexisting cardiovascular or other diseases) were sought by computer-based searches, scanning the reference lists of all relevant studies and review articles, hand-searching of relevant journals, and correspondence with authors of studies. Computer searches used Medline, PubMed, Web of Science, and Embase databases used keywords relating to uric acid in combination with CHD (e.g., coronary heart disease, ischemic heart disease, vascular disease, MI, and atherosclerosis). Relevant endpoints included nonfatal MI (generally using World Health Organization criteria) and CHD death (generally using International Classification of Disease criteria).

The following factors were abstracted from each study: numbers of cases and controls, mean age of cases and controls, mean number of cases and controls, mean age of patients, and mean number of patients. The factors used to adjust for in multivariable analyses were age, sex, current smoking status, body mass index, total serum cholesterol and triglycerides, and various markers of socioeconomic status related to occupation, education, home ownership, and type of accommodation. We assessed variation in the strength of association according to pre-specified sub-groups, using likelihood ratio tests for interaction after adjusting for these factors, with 99% confidence intervals (CIs) used in these exploratory analyses.

For the meta-analysis, studies of serum uric acid and CHD published before May 2003 with greater than a year's follow-up conducted in essentially general populations (i.e., excluding cohorts defined on the basis of preexisting cardiovascular or other diseases) were sought by computer-based searches, scanning the reference lists of all relevant studies and review articles, hand-searching of relevant journals, and correspondence with authors of studies. Computer searches used Medline, PubMed, Web of Science, and Embase databases used keywords relating to uric acid in combination with CHD (e.g., coronary heart disease, ischemic heart disease, vascular disease, MI, and atherosclerosis). Relevant endpoints included nonfatal MI (generally using World Health Organization criteria) and CHD death (generally using International Classification of Disease criteria).

The following factors were abstracted from each study: numbers of cases and controls, mean age of cases and...
Table 3. Relative Odds of Coronary Heart Disease in Individuals Who Had Serum Uric Acid in the Top Third of the Sex-Specific Distribution of Controls Relative to Those Who Had Values in the Bottom Third of This Distribution in the Reykjavik Study

| Participants in Analyses | Cut-Off Levels Used | Number of Cases | Number of Controls | Odds Ratio (95% CI) Adjusted For: |
|-------------------------|---------------------|-----------------|-------------------|----------------------------------|
|                         |                     | Top | Middle | Bottom | Age and Period | Age, Period, and Smoking | Age, Period, Smoking, Risk Factors | Age, Period, Smoking, Risk Factors, and Socioeconomic Status |
| All 2,456 cases and 3,962 controls | Serum uric acid in males (339 and 286 μmol/l) | 646 | 608 | 519 | 854 | 949 | 933 | 1.39 | (1.20–1.61) | 1.44 | (1.24–1.68) | 1.12 | (0.94–1.33) | 1.12 | (0.94–1.33) |
|                         | Serum uric acid in females (280 and 232 μmol/l) | 264 | 201 | 218 | 393 | 377 | 456 | 1.42 | (1.13–1.79) | 1.49 | (1.18–1.89) | 1.11 | (0.85–1.44) | 1.12 | (0.85–1.46) |
| 2,080 cases and 3,962 controls without evidence of coronary heart disease at entry | Serum uric acid in males (339 and 286 μmol/l) | 910 | 809 | 737 | 1,247 | 1,326 | 1,389 | 1.39 | (1.23–1.58) | 1.45 | (1.28–1.65) | 1.11 | (0.96–1.29) | 1.12 | (0.97–1.30) |
|                         | Serum uric acid in males and females combined | 523 | 521 | 444 | 854 | 949 | 933 | 1.34 | (1.14–1.57) | 1.39 | (1.18–1.63) | 1.07 | (0.89–1.29) | 1.08 | (0.90–1.31) |

* Systolic blood pressure, total cholesterol, triglycerides, body mass index, smoking (former or current, including number cigs per day), FEV1, history of diabetes

** Odds ratios (males and females combined) using alternative comparisons were: 1.24 (0.99–1.55) top fifth vs. bottom fifth; 1.22 (1.03–1.45) top quarter vs. bottom quarter; 1.08 (1.02–1.15) per standard deviation increase. Sex-specific odds ratios using thirds of the overall (not sex-specific) distribution of serum uric acid were: in males, 1.19 (0.98–1.43); in females 1.34 (0.98–1.82).

DOI: 10.1371/journal.pmed.0020076.t003

Results

The Reykjavik Study

The mean age at CHD event among cases was 70.2 (SD, 9.7) y. There were highly significant differences between cases and controls with respect to established vascular risk factors such as smoking, body mass index, blood pressure, and serum lipid concentrations (Table 2). Serum uric acid values were highly significantly associated with male sex, nonmanual occupation, body mass index, diastolic blood pressure, triglycerides, and serum creatinine (p < 0.0001 for each), although most of these associations weakened after adjustment for other vascular risk factors (Table S1). In 379 participants who provided paired blood samples, on average about 12 y apart, the within-individual correlation coefficient among serum uric acid values was 0.60 (CI, 0.54–0.66), similar to the decade–to-decade consistency observed in values of systolic blood pressure [0.66 (CI, 0.60–0.72)] and total serum cholesterol [0.60 (CI, 0.54–0.66)] in these participants.

The odds ratio for CHD was 1.39 (CI, 1.20–1.61; Wald test statistic, $\chi^2_1 = 18.4$) in males in the top third compared with those in the bottom third of baseline serum uric acid levels (tertile cut-offs, > 339 versus < 286 μmol/l [Table 3]), and this fell to 1.12 (CI, 0.94–1.33; $\chi^2_1 = 1.5$) after adjustment for smoking, other established risk factors, and indicators of socioeconomic status (Table 3). The odds ratio for CHD was 1.42 (CI, 1.13–1.79; $\chi^2_1 = 9.1$) in females in the top third compared with those in the bottom third of baseline serum uric acid levels (tertile cut-offs, > 280 μmol/l), and this fell to 1.12 (CI, 0.85–1.46; $\chi^2_1 = 0.6$) after adjustment for smoking, other established risk factors, and indicators of socioeconomic status. In a combined analysis of males and females, the odds ratio for CHD was 1.39 (CI, 1.23–1.58; $\chi^2_1 = 27.2$) and this fell to 1.12 (CI, 0.97–1.30; $\chi^2_1 = 2.4$) after adjustment. In analyses restricted to the 2,083 cases without evidence of CHD at baseline, the adjusted odds ratios fell further to 1.08 (CI, 0.90–1.31) in males and 1.00 (CI, 0.75–1.33) in females (Table 3), but the findings were materially unchanged in analyses excluding the 200 CHD cases with "possible" MI or in analyses varying cut-off levels (e.g., by quarters, fifths, or increases of 1 SD; see Table 3 legend). Figure 1 indicates that there was no substantial variation in the strength of association between serum uric acid and CHD at different levels of established risk factors, and, in particular, there was no good evidence of interactions with sex or systolic blood pressure (sex, $\chi^2_1 = 0.03$, p = 0.86; smoking, $\chi^2_1 = 0.28$, p = 0.60; body mass index, $\chi^2_2 = 1.13$, p = 0.57; total cholesterol, $\chi^2_2 = 2.42$, p = 0.30; systolic blood pressure, $\chi^2_2 = 4.63$, p = 0.10).
In aggregate, 16 prospective reports [6,14,15,16,17,18,20,21,22,23,24,25,26,27] on serum uric acid (including the present study) have involved a total of 9,458 CHD cases and 155,084 controls, with a weighted mean age at entry of 50 y and weighted mean follow-up of 10.5 y (Table 4). Studies were conducted in the USA [22,23,24,25,28], Western Europe [6,14,15,17,18,20,27], Israel [21], and Japan [16,26], and all reported adjustment for at least smoking and some other established risk factors. Overall, in a comparison of individuals with serum uric acid values in the top third with those in the bottom third of the population, the relative risk for CHD was 1.13 (CI, 1.07–1.20; Figure 2), with statistically compatible results in males and females ($\chi^2 = 1.1; p = 0.3$). In a subsidiary analysis of seven studies [20,22,23,24,25,27], involving 6,357 CHD cases and 65,978 controls, all of which excluded individuals with known cardiovascular disease at the baseline examination, the relative risk for CHD was 1.10 (CI, 1.03–1.18). There was significant heterogeneity among the 25 sex-specific study estimates ($\chi^2 = 38.1; p = 0.02$), but only some of this was explained by study characteristics such as sample size ($\chi^2 = 11.1$), geographical location ($\chi^2 = 1.0$), sampling framework ($\chi^2 = 0.5$), degree of adjustment for possible confounders ($\chi^2 = 10.0$), duration of follow-up ($\chi^2 = 0.1$), and assay type ($\chi^2 = 4.2$) (Figure 3). In a random-effects model, that takes additional account of study variation and the joint impact of these characteristics, only degree of adjustment for possible confounders remained a significant source of heterogeneity at the 1% level of significance (sex, $p = 0.36$; sample size, $p = 0.41$; geographical location, $p = 0.71$; sampling framework, $p = 0.02$; degree of adjustment for possible confounders, $p = 0.001$; duration of follow-up, $p = 0.67$; and assay type, $p = 0.06$).

**Discussion**

The present report provides prospective evidence from the largest study so far of serum uric acid and CHD—plus a meta-analysis of 15 previous relevant studies—involving a total of more than 9,000 incident cases and more than 150,000 controls. The overall findings suggest that individuals with baseline serum uric acid values in the top third of the population have about a 10% greater risk of CHD over the
### Table 4. Prospective Studies of Serum Uric Acid and Coronary Heart Disease in Essentially General Populations: Study Characteristics

| Study     | Geographical Location | Population/Sampling Method\(^a\) | Year(s) of Baseline Survey | Number of Controls | Number of CHD Cases | Age Range (y) | Percent Male | Approximate Mean Duration of Follow-Up (y) | Approximate Mean Uric Acid (SD) \(\mu\)mol/l | Assay                                      |
|-----------|-----------------------|----------------------------------|---------------------------|-------------------|-------------------|---------------|-------------|------------------------------------------|-------------------------------------------|-------------------------------------------|
| Reykjavik | Iceland               | Population registry/complete birth cohorts | 1967–1991                | 2,456             | 3,962             | 34–79         | 48           | 20                                       | 300 (70)                                   | Technicon auto-analyzer I N-13B method |
| Malmo     | Sweden                | Population register/complete birth cohort | 1975–1980                  | 2,096             | 29,790            | 27–61         | 69           | 13                                       | 300 (30)                                   | Uricase method                             |
| IHDS      | Israel                | Civil servant register/random     | 1963                      | 1,083             | 8,826             | 40–75         | 100          | 20                                       | 280 (30)                                   | NS                                        |
| Honolulu  | USA                   | Service registration record/complete | 1965–1968                 | 681               | 5,730             | Mn = 54       | 100          | 7                                        | 340                                       | Technicon auto-analyzer N-13B method |
| BRHS      | UK                    | GP register/random                | 1976–1980                 | 643               | 1,278             | 40–59         | 100          | 17                                       | 360 (70)                                   | NS                                        |
| Framingham| USA                   | Community register/random         | 1971–1976                 | 617               | 6,762             | Mn = 47       | 45           | 17                                       | 330 (70)                                   | Phosphotungstic acid                      |
| NHANES I and NHEFS | USA | Population register/random | 1971–1975                 | 421               | 5,677             | 25–74         | 46           | 16                                       | 330 (90)                                   | Phosphotungstic acid                      |
| ARIC      | USA                   | Listing of households/random      | 1987–1989                 | 392               | 13,112            | 45–64         | 43           | 8                                        | 360 (40)                                   | Uricase method                             |
| PROCAM    | Germany               | Employment register/complete      | 1979–1985                 | 373               | 8,110             | 16–78         | 63           | 7                                        | 310 (30)                                   | Uricase method                             |
| Edinburgh Artery | Scotland     | GP register/random               | 1988                      | 294               | 1,159             | 55–74         | 50           | < 10                                      | 310 (30)                                   | Uricase method                             |
| GRIPS     | Germany               | Population register/random        | 1982                      | 107               | 5,122             | 49–60         | 100          | 9                                        | 360 (50)                                   | NS                                        |
| BRNH      | Belgium               | Electoral register/random         | 1981–1984                 | 92               | 8,415             | 25–74         | 53           | NS                                       | 330                                       | NS                                        |
| Japanese Workers | Japan     | Employee health register/complete | 1975–1982                 | 72                | 45,604            | 25–60         | 100          | 5                                        | 340 (40)                                   | Phosphotungstic acid and uricase peroxidase |
| CHA       | USA                   | Employment register/complete      | 1989–1990                 | 65                | 6,730             | 35–64         | 0            | 12                                       | 330 (70)                                   | Technicon autoanalyzer N-13B method       |
| MONICA Augsburg | Germany | Population register/random  | 1984–1985                 | 60               | 945               | 25–64         | 51           | 8                                        | 330 (80)                                   | Uricase method                             |
| Osaka     | Japan                 | Workforce and community register/NS | 1990–1996                 | 36               | 11,762            | 21–89         | 68           | 5                                        | 320 (30)                                   | NS                                        |

\(^a\) Sampling method: Random, a randomly selected subset of eligible persons was invited to participate; complete, all eligible persons in the study population were invited to participate.

\(^b\) Only men were included in analyses, due to a small numbers of female cases: BRNH, 26 women; Osaka, 4 women; MONICA Augsburg, number of female cases not stated.

\(^c\) Duration of follow-up was “at least 10 years.”

Table abbreviations: NS, not specified; Mn, mean; GP, general practice; SD, standard deviation. Study abbreviations: IHDS, Israeli ischemic Heart Disease Study; BRNS, British Regional Heart Study; NHANES, National Health and Nutrition Examination Survey; NHEFS, NHANES I Epidemiological Follow-up Study; PROCAM, Prospective Cardiovascular Munster Study; ARIC, Atherosclerosis Risk in Communities; GRIPS, Göttingen Risk Incidence and Prevalence Study; CHA, Chicago Heart Association Detection Project in Industry; BRNH, Belgium Interuniversity Research on Nutrition and Health; MONICA, World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease.

DOI: 10.1371/journal.pmed.0020076.T004
of cardiovascular medication, history of hypertension, and history of diabetes. PTA, phosphotungstic acid.

practice registers; §, risk factors adjusted for included: smoking, blood pressure, total cholesterol, triglycerides, alcohol consumption, obesity, use of CHD.

serum uric acid levels are unlikely to be a major determinant density-lipoprotein cholesterol [1,30], but they suggest that formation of free radicals or through the oxidation of low-potentially relevant vascular effects (such as through the be involved in the causation of CHD through a number of address the question of whether or not serum uric acid may provide no good evidence to support previous claims that the association between serum uric acid and CHD is independent from possible confounders; the odds ratio was only 1.02 (CI, 0.91–1.14), which is not significant, in the eight studies with the most complete reported adjustment for possible confounders (Figure 3). The present data also provide no good evidence to support previous claims that the association between serum uric acid and CHD is stronger in females than in males [5], or stronger at higher levels of established risk factors, such as in individuals with higher blood pressure recordings [29].

The main implication of these data is to refute suggestions made throughout the past half-century that measurement of serum uric acid can importantly enhance the prediction of CHD in general populations. These data do not directly address the question of whether or not serum uric acid may be involved in the causation of CHD through a number of potentially relevant vascular effects (such as through the formation of free radicals or through the oxidation of low-density-lipoprotein cholesterol [1,30]), but they suggest that serum uric acid levels are unlikely to be a major determinant of CHD.

Supporting Information

Table S1.

Comparison of Baseline Values of Risk Factors and Other Characteristics in Controls in the Reykjavik Study by Thirds of Serum Uric Acid Concentration

Found at DOI: 10.1371/journal.pmed.0020076.st001 (67 KB DOC).

Figure 3. Prospective Studies of the Association of Serum Uric Acid and CHD, Grouped by Various Characteristics

Conventions are the same as in Figure 1. †, each sex-specific estimate was treated as a “study”; §, two studies (6 and 13) were drawn from general practice registers; §§, risk factors adjusted for included: smoking, blood pressure, total cholesterol, triglycerides, alcohol consumption, obesity, use of cardiovascular medication, history of hypertension, and history of diabetes. PTA, phosphotungstic acid.

DOI: 10.1371/journal.pmed.0020076.g003

subsequent decade than those in the bottom third (with the likelihood that this association would be about twice as strong if based on long-term usual levels of serum uric acid). It is likely, however, that this modest association has been exaggerated by the preferential publication of striking findings in smaller studies (“publication bias”), or by residual confounding by established risk factors, or both. For example, the observation of weaker associations in studies with more comprehensive adjustment for possible confounders lessens the likelihood that any association between serum uric acid and CHD is independent from possible confounders; the odds ratio was only 1.02 (CI, 0.91–1.14), which is not significant, in the eight studies with the most complete reported adjustment for possible confounders (Figure 3). The present data also provide no good evidence to support previous claims that the association between serum uric acid and CHD is stronger in females than in males [5], or stronger at higher levels of established risk factors, such as in individuals with higher blood pressure recordings [29].

The main implication of these data is to refute suggestions made throughout the past half-century that measurement of serum uric acid can importantly enhance the prediction of CHD in general populations. These data do not directly address the question of whether or not serum uric acid may be involved in the causation of CHD through a number of potentially relevant vascular effects (such as through the formation of free radicals or through the oxidation of low-density-lipoprotein cholesterol [1,30]), but they suggest that serum uric acid levels are unlikely to be a major determinant of CHD.

Acknowledgments

This work was supported by a program grant from the British Heart Foundation and by the Raymond and Beverly Sackler Award in the Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We are grateful to Adam Dickinson for assistance with correspondence to investigators. The following investigators kindly provided additional data from their studies: Riitta Antikainen, Dirk de Bacquer, Calle Bengtsson, Lori Boland, Christopher Bulpitt, Perry Fowkes, Uri Goldbourt, Bo Hedblad, Sandy Irving, Ulrich Keil, Amanda Lee, Angela Liese, Jack Medalie, Dorothea Nagal, Shinichi Sato, Helmet Schulte, and Masako Tomita.

References

1. Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14: 613–631.
2. Gertler MM, Garn SM, Levine SA (1951) Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34: 1421–1431.
3. Rich MW (2000) Uric acid: Is it a risk factor for cardiovascular disease? Am J Cardiol 85: 1018–1021.
4. Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekelle RB, et al. (1979) Uric acid: A risk factor for coronary heart disease? Circulation 59: 969–977.
5. Freedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiological Follow-up Study. Am J Epidemiol 141: 637–644.
6. Wannamethee SG, Shaper AG, Whincup PH (1997) Serum urate and the risk of major coronary heart disease events. Heart 78: 147–153.
7. Jo´ nsdo´ ttir LS, Sigfsson N, Gudnason V, Sigvaldason H, Thorgeirsson G (2002) Do lipids, blood pressure, diabetes and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik study. J Cardiovasc Risk 9: 67–76.
8. Hawk P, Oser B, Summerw M (1954) Practical physiological chemistry. 13th edition. New York: Blakison. 564 p.
9. Puddu PE, Lanti M, Menotti A, Mancini M, Zanchetti A, et al. (2001) Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol 56: 243–251.
10. Cullen KJ, Knunnan MW, Ward NJ (1993) Alcohol and mortality in Busselton, Western Australia. Am J Epidemiol 137: 242–248.
11. Bengtsson C, Lapinhus L, Stendahl C, Waldenstrom J (1988) Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 224: 549–555.
12. Reunanen A, Takkunen H, Knekt P, Aromaa A (1982) Hyperuricaemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl 668: 49–59.
13. Fessel WJ (1980) High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 68: 401–404.
14. Love GD, Foxkes FG, Dawes J, Donnatt PT, Lennie SE, et al. (1993) Blood viscosity, fibrinogen, and activation of coagulation and leucocytes in
peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87: 1915–1920.
15. Cremer P, Nagel D, Labrot B, Mann H, Muche R, et al. (1994) Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24: 444–453.
16. Kitamura A, Iso H, Iida M, Naito Y, Sato S, et al. (2002) Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 112: 104–109.
17. Assmann G, Schulte H, Cullen P (1997) New and classical risk factors—The Munster heart study (PROCAM). Eur J Med Res 2: 237–242.
18. De Bacquer D, De Bacquer G, De Buyzere M, Kornitzer M (1998) Is low serum chloride level a risk factor for cardiovascular mortality? J Cardiovasc Risk 5: 177–184.
19. Danesch J, Collins R, Appleby P, Petro R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 279: 1477–1482.
20. Peterson B, Trell E (1985) Raised serum urate concentration as risk factor for premature mortality in middle aged men: Relation to death from cancer. Br Med J (Clin Res Ed) 287: 7–9.
21. Medalie JH, Kahn HA, Neufeld HN, Riss E, Goldbourt U (1973) Five-year myocardial infarction incidence. II. Association of single variables to age and birthplace. J Chronic Dis 26: 325–349.
22. Iribarren C, Sharp DS, Curb JD, Yano K (1996) High uric acid: A metabolic marker of coronary heart disease among alcohol abstainers. J Clin Epidemiol 49: 673–678.
23. Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 131: 7–13.
24. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiological follow-up study, 1971–1991. National Health and Nutrition Examination Survey. JAMA 283: 2404–2410.
25. Mortality JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD (2000) Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 10: 136–145.
26. Tomita M, Miwano S, Yamanaka H, Hosoda Y, Sakuma K, et al. (2000) Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 10: 403–409.
27. Liese AD, Hense HW, Loebl H, Doring A, Tietze M, et al. (1999) Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 10: 391–397.
28. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J (1989) Serum uric acid and 11.5-year mortality of middle-aged women: Findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 42: 257–267.
29. Alderman MH (2002) Uric acid and cardiovascular risk. Curr Opin Pharmacol 2: 126–130.
30. Ward HJ (1998) Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352: 670–671.

Patient Summary

Background. Defining which risk factors are important for disease is useful for clinicians and patients not only because the presence of risk factors allows the prediction of who is more likely to get a disease, but also because they provide some insight into the underlying causes of disease. One such suspected risk factor for coronary heart disease is the level of uric acid in the blood. The debate over whether uric acid is useful for predicting heart disease has been going on for over fifty years. Most evidence for risk factors comes from studies of populations, in which it can be hard to tease out the effects of many different factors; often studies come to different conclusions. One way of finding out which results are reliable is to pool the results of many studies.

What Did the Researchers Find? They looked at the uric acid levels of around 2,500 people with coronary heart disease and almost 4,000 controls measured at the start of a large study in Iceland, and then investigated whether there was a relation between levels of uric acid and development of heart disease. After adjusting for all the other factors that could affect the chance of heart disease, they found that uric acid did not predict heart disease. They then combined these results with those from 15 other studies, and confirmed the findings.

What Do These Findings Mean? After fifty years, it now seems clear that measurement of uric acid does not help to predict heart disease. It may still be involved in triggering heart disease, but any effect must be subtle.

Where Can I Get More Information? The National Heart Lung and Blood Institute has many pages of information on heart disease: http://www.nhlbi.nih.gov/health/public/heart/index.htm#ami